GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kobo Biotech Ltd (BOM:531541) » Definitions » Cash-to-Debt

Kobo Biotech (BOM:531541) Cash-to-Debt : N/A (As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Kobo Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kobo Biotech's cash to debt ratio for the quarter that ended in Jun. 2024 was N/A.

The historical rank and industry rank for Kobo Biotech's Cash-to-Debt or its related term are showing as below:

BOM:531541' s Cash-to-Debt Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.01
Current: 0.01

During the past 13 years, Kobo Biotech's highest Cash to Debt Ratio was 0.01. The lowest was 0.00. And the median was 0.00.

BOM:531541's Cash-to-Debt is ranked worse than
97.45% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs BOM:531541: 0.01

Kobo Biotech Cash-to-Debt Historical Data

The historical data trend for Kobo Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kobo Biotech Cash-to-Debt Chart

Kobo Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 - - 0.01

Kobo Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.01 N/A 0.01 N/A

Competitive Comparison of Kobo Biotech's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Kobo Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kobo Biotech's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kobo Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kobo Biotech's Cash-to-Debt falls into.



Kobo Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kobo Biotech's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Kobo Biotech's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kobo Biotech  (BOM:531541) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Kobo Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kobo Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Kobo Biotech Business Description

Traded in Other Exchanges
N/A
Address
Saki Vihar Road, Unit 104, HYDE Park, Opp. Ansa Industrial Estate, Andheri (East), Mumbai, MH, IND, 400 072
Kobo Biotech Ltd is a pharmaceutical company. Its business comprises the manufacturing and sale of APIs (Active Pharmaceutical Ingredients) based on fermentation technology and Intermediates to pharmaceutical companies.

Kobo Biotech Headlines

No Headlines